1. Home
  2. URGN vs FNKO Comparison

URGN vs FNKO Comparison

Compare URGN & FNKO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • FNKO
  • Stock Information
  • Founded
  • URGN 2004
  • FNKO 2017
  • Country
  • URGN United States
  • FNKO United States
  • Employees
  • URGN N/A
  • FNKO N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • FNKO Recreational Games/Products/Toys
  • Sector
  • URGN Health Care
  • FNKO Consumer Discretionary
  • Exchange
  • URGN Nasdaq
  • FNKO Nasdaq
  • Market Cap
  • URGN 547.1M
  • FNKO 543.2M
  • IPO Year
  • URGN 2017
  • FNKO 2017
  • Fundamental
  • Price
  • URGN $12.84
  • FNKO $12.09
  • Analyst Decision
  • URGN Strong Buy
  • FNKO Buy
  • Analyst Count
  • URGN 5
  • FNKO 4
  • Target Price
  • URGN $44.50
  • FNKO $10.63
  • AVG Volume (30 Days)
  • URGN 764.9K
  • FNKO 405.4K
  • Earning Date
  • URGN 11-12-2024
  • FNKO 10-31-2024
  • Dividend Yield
  • URGN N/A
  • FNKO N/A
  • EPS Growth
  • URGN N/A
  • FNKO N/A
  • EPS
  • URGN N/A
  • FNKO N/A
  • Revenue
  • URGN $85,011,000.00
  • FNKO $1,067,536,000.00
  • Revenue This Year
  • URGN $16.49
  • FNKO N/A
  • Revenue Next Year
  • URGN $57.58
  • FNKO $7.52
  • P/E Ratio
  • URGN N/A
  • FNKO N/A
  • Revenue Growth
  • URGN 17.22
  • FNKO N/A
  • 52 Week Low
  • URGN $10.60
  • FNKO $5.36
  • 52 Week High
  • URGN $20.70
  • FNKO $12.61
  • Technical
  • Relative Strength Index (RSI)
  • URGN 49.60
  • FNKO 57.08
  • Support Level
  • URGN $11.84
  • FNKO $11.46
  • Resistance Level
  • URGN $13.54
  • FNKO $12.23
  • Average True Range (ATR)
  • URGN 0.82
  • FNKO 0.44
  • MACD
  • URGN 0.08
  • FNKO -0.09
  • Stochastic Oscillator
  • URGN 65.88
  • FNKO 62.04

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About FNKO Funko Inc.

Funko Inc is an us-based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.

Share on Social Networks: